In the context of TSC-related epilepsy, the use of mTOR inhibitor drugs, such as everolimus, represents a possibility for a treatment for refractory epilepsy, targeting the genetic cause.5, 11Thus, this systematic review aims to evaluate the efficacy of everolimus in controlling refractory epilepsy in pediatric patients with tuberous sclerosis. The gene discussed is MTOR; the disease is epilepsy.